Viking Therapeutics, Inc. (VKTX) Stock Price & How to Invest

Viking Therapeutics (VKTX) is a clinical-stage biopharmaceutical company developing novel therapies for metabolic and endocrine disorders. Its highest-profile program is VK2735, a dual GLP-1 and GIP receptor agonist for obesity, being developed in both injectable and oral forms, which puts Viking among the most closely watched challengers in the booming weight-loss drug market dominated by Novo Nordisk and Eli Lilly. Viking is also developing VK2809, a thyroid-hormone receptor beta agonist for non-alcoholic steatohepatitis (NASH/MASH), VK0214 for a rare disease (X-linked adrenoleukodystrophy), and VK3019, an amylin receptor agonist. As a clinical-stage company, Viking has no approved products and generates no product revenue, funding itself from cash on its balance sheet. Headquartered in San Diego, California, VKTX is a speculative, binary biotech whose value hinges on clinical-trial outcomes and the eventual commercial path for its lead obesity drug.

The late-stage program is now in place. The injectable VANQUISH Phase 3 trials are fully enrolled, with about 4,500 adults in VANQUISH-1 and about 1,000 adults with type 2 diabetes in VANQUISH-2, testing weekly doses over 78 weeks. On October 14, 2026 Viking started SUNRISE, the Phase 3 program for oral VK2735: two 68-week trials of about 560 adults each, one without and one with type 2 diabetes, testing once-daily doses of 27.5 mg, 35 mg and 55 mg against placebo. That follows the Phase 2 VENTURE-Oral study, where 13 weeks of treatment produced mean weight loss of up to 12.2%, with mostly mild or moderate, early gastrointestinal side effects.

Running those trials is expensive. Viking lost about $535 million over the twelve months to June 2026, including about $128 million in the second quarter, when its loss of $1.10 per share was narrower than the $1.21 consensus. It held about $502 million of cash with almost no debt at the end of June. The stock closed near $26.17 on October 16, 2026, down about 26% year to date, 25% over one year and 31% over three months, close to its 52-week low of $25.28. Analysts remain bullish: 20 cover it with a strong-buy consensus and a mean target near $94.50, and UBS initiated coverage at buy with a $94 target in October. Third-quarter results are expected around October 28, 2026.

Viking is a clinical-stage biotech with no approved products and no product revenue, so it is highly speculative and potentially binary. A single disappointing trial readout, safety signal, or regulatory setback for VK2735 could sharply reduce the stock's value. The obesity market is intensely competitive, dominated by Novo Nordisk and Eli Lilly with deep resources and manufacturing scale, and crowded with other entrants. Viking's losses widened sharply as Phase 3 work began (about $535 million over the trailing twelve months against about $502 million of cash), so it may need to raise more capital, diluting shareholders. Manufacturing, commercialization, and pricing all remain unproven. The stock has fallen about 31% in three months to near its 52-week low despite bullish analyst targets, which shows how sentiment can move independently of the pipeline. This is a high-risk position whose outcome depends on clinical and regulatory events outside investors' control.

20 analysts publish price targets on VKTX, averaging $94.50 against a $25.17 price as of October 2026, or +275.4%. The published targets run from $38.00 to $125.00, a wide spread, and the ratings split 19 buy, 2 hold, 0 sell. Over the last six months there have been 2 raises and 2 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full VKTX forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Viking Therapeutics, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Lead obesity program (VK2735). VK2735 is a dual GLP-1 and GIP receptor agonist for obesity, now in Phase 3 in both injectable and oral forms. The most optimistic published target, $125.00, assumes this works close to its best case.

The case against. Viking is a clinical-stage biotech with no approved products and no product revenue, so it is highly speculative and potentially binary. The most pessimistic target, $38.00, is roughly what VKTX is worth if this bites instead.

Read the full bull and bear case on VKTX, including what would have to change to break either one. Walnut is not an investment adviser.

No. Viking Therapeutics, Inc. (VKTX) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Viking Therapeutics, Inc.'s investor relations page or your broker.

• Product revenue: ~$0 (no approved products)
• Net loss (TTM): ~$535 million; Q2 2026 ~$128 million
• EPS (Q2 2026): -$1.10 vs -$1.21 consensus; Q3 consensus ~-$1.06
• Cash vs debt: ~$502 million cash, ~$4 million debt (June 2026)
• Market cap: ~$3.3 billion at ~$26.17
• Price / book: ~7.5x
• Dividend yield: 0% (no dividend)
• Analyst view: 20 analysts, strong buy consensus, mean target ~$94.50

Viking has no earnings to value on a P/E basis; the stock is priced on the probability-weighted potential of its pipeline, above all VK2735 in obesity, and on acquisition speculation. At about $3.3 billion, the market is valuing two Phase 3 obesity programs at roughly $2.8 billion above cash, while analysts' targets imply far more. Cash runway matters because the annual loss now exceeds the cash balance, so additional fundraising could dilute holders. All figures are approximate and should be verified against current filings.

These are the investment theses VKTX naturally fits into. Each links to a full theme guide listing every other stock that belongs and the ETFs commonly used as a passive proxy.

Other names that sit close to VKTX: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get VKTX exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so VKTX sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where VKTX fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Viking Therapeutics (VKTX) is a speculative, clinical-stage play on the obesity-drug boom and on NASH/MASH, centered on its VK2735 GLP-1 candidate, now in Phase 3 in both injectable and oral form. Its value swings on trial readouts, regulatory progress, and takeover speculation rather than earnings, and the stock sits near its 52-week low even as analysts' average target is far higher. In a portfolio it behaves as a high-volatility, potentially binary position with significant downside if data disappoints, so most holders treat it as a small, risk-aware allocation.

Whether VKTX is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is VKTX a buy or a sell?, and where the stock could go from here in the VKTX stock forecast.

For income investors, whether VKTX pays a dividend and how the payout looks is covered in does VKTX pay a dividend? And to weigh VKTX against a peer, read the full side-by-side comparisons: VKTX vs LLY and VKTX vs NVO.